Exact Sciences (NASDAQ:EXAS) Price Target Lowered to $67.00 at Robert W. Baird

Exact Sciences (NASDAQ:EXAS) had its price objective cut by Robert W. Baird from $70.00 to $67.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “outperform” rating on the medical research company’s stock. Robert W. Baird’s target price indicates a potential downside of 6.31% from the company’s current price.

Several other brokerages also recently weighed in on EXAS. Benchmark decreased their price target on Exact Sciences from $91.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, August 1st. The Goldman Sachs Group decreased their target price on shares of Exact Sciences from $88.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, July 17th. Wells Fargo & Company assumed coverage on shares of Exact Sciences in a report on Tuesday, August 27th. They issued an “overweight” rating and a $75.00 price target for the company. Sanford C. Bernstein upped their target price on shares of Exact Sciences from $75.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Finally, Stifel Nicolaus reduced their price target on shares of Exact Sciences from $100.00 to $82.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Exact Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $79.73.

Exact Sciences Stock Performance

Shares of EXAS stock opened at $71.51 on Wednesday. Exact Sciences has a 52-week low of $40.62 and a 52-week high of $79.62. The stock’s 50-day moving average price is $67.27 and its 200 day moving average price is $56.67. The company has a quick ratio of 1.98, a current ratio of 2.17 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of $13.21 billion, a PE ratio of -74.49 and a beta of 1.27.

Insider Transactions at Exact Sciences

In related news, EVP Brian Baranick sold 929 shares of the company’s stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total value of $65,030.00. Following the completion of the transaction, the executive vice president now directly owns 12,758 shares in the company, valued at approximately $893,060. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 1.36% of the company’s stock.

Institutional Investors Weigh In On Exact Sciences

Institutional investors have recently bought and sold shares of the stock. Itau Unibanco Holding S.A. acquired a new position in shares of Exact Sciences in the 2nd quarter valued at $29,000. Capital Performance Advisors LLP acquired a new position in Exact Sciences in the third quarter valued at $35,000. Vestor Capital LLC acquired a new position in Exact Sciences in the third quarter valued at $46,000. V Square Quantitative Management LLC purchased a new stake in Exact Sciences during the third quarter valued at about $47,000. Finally, EverSource Wealth Advisors LLC increased its stake in Exact Sciences by 92.4% during the first quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company’s stock worth $49,000 after acquiring an additional 340 shares during the last quarter. 88.82% of the stock is currently owned by hedge funds and other institutional investors.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.